Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis

Journal of Medicinal Chemistry

Volumn 41, Issue 22, 1998, Pages 4207-4215

  Tong, Weida ^a,c   Collantes, Elizabeth R ^a,d   Welsh, William J ^a   Berglund, Barbara A ^b   Hewlett, Allyn C ^b  

^a UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c National Center for Toxicological Research   (United States)

^d MONSANTO COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXYDRONABINOL; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; ANANDAMIDE; CANNABINOID RECEPTOR; DEACETYLLEVONANTRADOL; DEXANABINOL; DRUG CARRIER; PROSTACYCLIN DERIVATIVE;

ARTICLE; DERIVATIZATION; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; ENANTIOMER; MOLECULAR DYNAMICS; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR AFFINITY; STEREOCHEMISTRY;

ARACHIDONIC ACIDS; CANNABINOIDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032561388     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970239z     Document Type: Article

References (45)

1. 1-Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man. Pharmacol. Rev. 1988, 38, 21-43.
2. 1-Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man. Pharmacol. Rev. 1988, 38, 21-43.
3. (c) Razdan, R. K. Structure-Activity Relationships in Cannabinoids. Pharmacol. Rev. 1986, 38, 75-149.
4. (a) Bloom, A. S.; Dewey, W. L.; Harris, L. S.; Brosius, K. K. 9-nor-9β-hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity; comparisons with morphine. J. Pharmacol. Exp. Ther. 1977, 200, 263-270.
5. (b) Wilson, R. S.; May, E. L.; Martin, B. R.; Dewey, W. L. 9-Nor-9β-hydroxyhexahydro-cannabinols: Synthesis, Some Behavioral and Analgesic Properties, and Comparison with the Tetrahydrocannabinols. J. Med. Chem. 1976, 19, 1165-1167.
6. (a) Melvin, L. S.; Johnson, M. R. Structure-Activity Relation-ships of Tricyclic and Nonclassical Bicyclic Cannabinoids. NIDA Res. Monogr. 1987, 79, 31-47.
7. (b) Howlett, A. C.; Johnson, M. R.; Melvin, L. S.; Milne, G. M. Nonclassical Cannabinoid Analgesics Inhibit Adenylate Cyclase: Development of a Cannabinoid Receptor Model. Mol Pharmacol. 1988, 33, 297-302.
8. (a) Melvin, L. S.; Milne, G. M.; Johnson, M. R.; Wilken, G. H.; Howlett, A. C. Structure-Activity Relationships Defining the ACD-Tricyclic Cannabinoids: Cannabinoid Receptor Binding and Analgesic Activity. Drag Des. Discovery 1995, 13, 155-166.
9. (b) Melvin, L. S.; Milne, G. M.; Johnson, M. R.; Subramaniam, B.; Wilken, G. H.; Howlett, A. C. Structure-Activity Relationships for Cannabinoid Receptor-Binding and Analgesic Activity: Studies of Bicyclic Cannabinoid Analogues. Mol. Pharmacol. 1993, 44, 1008-1015.
10. Johnson, M. R.; Melvin, L. S.; Milne, G. M. Prototype Cannabinoid Analgesics, Prostaglandins and Opiates - A Search for Points of Mechanistic Interaction. Life Sci. 1982, 31, 1703-1706.
11. Xie, X. Q.; Yang, D. P.; Melvin, L. S.; Makriyannis, A. Conformational Analysis of the Prototype Nonclassical Cannabinoid CP-47,497, Using 2D NMR and Computer Molecular Modeling. J. Med. Chem. 1994, 37, 1418-1426.
12. Rosenqvist, E.; Ottersen, T. The Crystal and Molecular Structure of Δ-9-Tetrahydrocannabinolic Acid. Acta Chem. Scand. Series B Org. Chem. Biochem. 1975, B29, 379-384.
13. Milne, G. M.; Johnson, M. R. Levonantradol: a Role for Central Prostanoid Mechanisms. J. Clin. Pharmacol. 1981, 21, 3678.
14. (a) Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. Science 1992, 258, 1946-1949.
15. (b) Vogel, Z.; Barg, J.; Levy, R.; Saya, D.; Heldman, E.; Mechoulam, R. Anandamide, a Brain Endogenous Compound, Interacts Specifically with Cannabinoid Receptors and Inhibits Adenylate Cyclase. J. Neurochem. 1993, 61, 352-355.
16. (c) Smith, P. B.; Compton, D. R.; Welch, S. P.; Razdan, R. K.; Mechoulam, R.; Martin, B. R. The Pharmacological Activity of Anandamide, a Putative Endogenous Cannabinoid. in Mice. J. Pharmacol. Exp. Ther. 1994, 270, 219-227.
17. Hanus, L. A.; Gopher, A.; Almog, S.; Mechoulam, R. Two New Unsaturated Fatty Acid Ethanolamides in Brain that Bind to the Cannabinoid Receptor. J. Med. Chem. 1993, 36, 3032-3034.
18. Pinto, J. C.; Potie, F.; Rice, K. C.; Boring, D.; Johnson, M. R.; Evans, D. M.; Wilken, G. H.; Cantrell, C. H.; Howlett, A. C. Cannabinoid Receptor Binding and Agonist Activity Of Amides and Esters of Arachidonic Acid. Mol. Pharmacol. 1994, 46, 516-522.
19. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Med. Chem. 1988, 110, 5959-5967.
20. (a) Waller, C.; McKinney, J. D. Three-Dimensional Quantitative Structure-Activity Relationships of Dioxins and Dioxin-like Compounds: Model Validation and Ah Receptor Characterization. Chem. Res. Toxicol. 1995, 8, 847-858.
21. (b) Tong, W.; Collantes, E. R.; Chen, Y.; Welsh, W. J. A Comparative Molecular Field Analysis Study of N-Benzylpiperidines as Acetylcholinesterase Inhibitors. J. Med. Chem. 1996, 39, 380-387.
22. (c) Collantes, E. R.; Tong, W.; Welsh, W. J.; Zielinski, W. L. Use of Moment of Inertia in Comparative Molecular Field Analysis to Model Chromatographic Retention of Nonpolar Solutes. Anal. Chem. 1996, 68, 2038-2043.
23. (d) Welsh, W. J.; Tong, W.; Collantes, E. R.; Chickos, J. S.; Gagarin, S. G. Enthalpies of Sublimation and Formation of Polycyclic Aromatic Hydrocarbons (PAHs) Derived from Comparative Molecular Field Analysis (CoMFA): Application of Moment of Inertia for Molecular Alignment. Thermochim. Acta 1996, 290, 55-64.
24. Insight II and Discover are products of MSI, Inc., San Diego, CA.
25. Sybyl, including CoMFA and DISCO, is a product Tripos, Inc., St. Louis, MO.
26. Martin, Y. C.; Bures, M. G.; Danaher, E. A.; DeLazzer, J.; Lico, I.; Pavlik, P. A. A Fast New Approach to Pharmacophore Mapping and its Application to Dopaminergic and Benzodiazepine Agonist. J. Comput.-Aided Mol. Des. 1993, 7, 83.
27. Reggio, P. H.; Greer, K. V.; Cox, S. M. The Importance of the Orientation of the C9 Substituent to Cannabinoid Activity. J. Med. Chem. 1989, 32, 1630-1635.
28. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity: A Rapid Access to Atomic Charges. Tetrahedron 1980, 36, 3219-3228.
29. Wold, S.; Albans, C.; Dunn, W. J., III; Edlund, U.; Esbensen, K.; Geladi, P.; Hellberg, S.; Johanason, E.; Lindberg, W.; Sjostrom, M. In Multivariate Data Analysis in Chemistry; Kowalski, B., Ed.; Reidel: Dordrecht, The Netherlands, 1984.
30. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E. Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
31. (a) Hewlett, A. C. Pharmacology of Cannabinoid Receptors. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 607-634.
32. (b) Howlett, A. C.; Berglund, B. A.; Melvin, L. S. Cannabinoid Receptor Agonists and Antagonists. Curr. Pharm. Des. 1995, 1, 343-354.
33. (a) Johnson, M. R.; Melvin, L. S.; Althuis, T. H.; Bindra, J. S.; Harbert, C. A.; Milne, G. M.; Weissman, A. Selective and Potent Analgesics Derived from Cannabinoids. J. Clin. Pharmacol. 1981, 21, 271S-282S.
34. (b) Adams, I. B.; Ryan, W.; Singer, M.; Thomas, B. F.; Compton, D. R.; Razdan, R. K.; Martin, B. R. Evaluation of Cannabinoid Receptor Binding and In Vivo Activities for Anandamide Analogues. J. Pharmacol. Exp. Ther. 1995, 273, 1172-1181.
35. (c) Mechoulam, R.; Hanus, L.; Martin, B. R. Search for Endogenous Ligands of the Cannabinoid Receptor. Biochem. Pharmacol. 1994, 48, 1537-1544.
36. Thomas, B. F.; Adams, I. B.; Mascarella, S. W.; Martin, B. R.; Razdan, R. K. Structure-Activity Analysis of Anandamide Analogues: Relationship to a Cannabinoid Pharmacophore. J. Med. Chem. 1996, 39, 471-479.
37. Johnson, M. R.; Melvin, L. S. In Cannabinoids as Therapeutic Agents; Mechoulam, R., Ed.; CRC Press: Boca Raton, FL. 1986; pp 121-145.
38. 1Tetrahydrocannabinol in Mice. Biochem. Pharmacol. 1973, 22, 175-184.
39. (b) Wilson, R. S.; May, E. L. Analgesic Properties of the Tetrahydrocannabinols, Their Metabolites, and Analogues. J. Med. Chem. 1975, 18, 700-703.
40. 9-Tetrahydrocannabinol. Science 1972, 177, 633-635.
41. Burstein, S. H.; Young, J. K.; Wright, G. E. Relationship Between Eicosanoids and Cannabinoids. Are Eicosanoids Cannabimimetic Agents? Biochem. Pharmacol 1995, 50, 1735-1742.
42. Barnett-Norris, J.; Guarnieri, F.; Reggio, P. H. Conformational Memories and the Exploration of Biologically Relevant Conformations of Anandamide. 1997 Symposium Abstracts; International Cannabinoid Research Society, 1997; p 5.
43. 8-THC-dimethylheptyl to Inhibit Adenylate Cyclase and Bind to the Cannabinoid Receptor, Neuropharmacology 1990, 29, 161-165.
44. Stegeman, R.; Pawlitz, J.; Stevens, A.; Gierse, J.; Stallings, W.; Kurumbail, R. Mechanism of Cyclooxygenase Reactions: Structure of Arachidonic Acid Bound to Cyclooxygenase-2. American Crystallographic Association, 1998; Abstract.
45. 1 Cannabinoid Receptor Agonists CP55244 and WIN55212-2. In Rational Drug Design ACS Symposium Series; Parrill, A. L., Reddy, M. R., Eds.; American Chemical Society: Washington, DC, 1998.